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ARTICLE
Mutations in CRADD Result in Reduced
Caspase-2-Mediated Neuronal Apoptosis and Cause
Megalencephaly with a Rare Lissencephaly Variant
Nataliya Di Donato,1,2,17,* Ying Y. Jean,3 A. Murat Maga,4,5 Briana D. Krewson,6 Alison B. Shupp,6
Maria I. Avrutsky,3 Achira Roy,2 Sarah Collins,2 Carissa Olds,2 Rebecca A. Willert,6 Agnieszka M. Czaja,6
Rachel Johnson,6 Jessi A. Stover,6 Steven Gottlieb,7 Deborah Bartholdi,8 Anita Rauch,9 Amy Goldstein,10
Victoria Boyd-Kyle,6 Kimberly A. Aldinger,2 Ghayda M. Mirzaa,2,11 Anke Nissen,12 Karlla W. Brigatti,6,13
Erik G. Puffenberger,6,13 Kathleen J. Millen,2 Kevin A. Strauss,6,13,14 William B. Dobyns,2,11,15,17
Carol M. Troy,3,16,17 and Robert N. Jinks6,17,*
Lissencephaly is a malformation of cortical development typically caused by deficient neuronal migration resulting in cortical thick-
ening and reduced gyration. Here we describe a ‘‘thin’’ lissencephaly (TLIS) variant characterized by megalencephaly, frontal predomi-
nant pachygyria, intellectual disability, and seizures. Trio-based whole-exome sequencing and targeted re-sequencing identified recessive
mutations of CRADD in six individuals with TLIS from four unrelated families of diverse ethnic backgrounds. CRADD (also known as
RAIDD) is a death-domain-containing adaptor protein that oligomerizes with PIDD and caspase-2 to initiate apoptosis. TLIS variants
cluster in the CRADD death domain, a platform for interactionwith other death-domain-containing proteins including PIDD. Although
caspase-2 is expressed in the developing mammalian brain, little is known about its role in cortical development. CRADD/caspase-2
signaling is implicated in neurotrophic factor withdrawal- and amyloid-b-induced dendritic spine collapse and neuronal apoptosis, sug-
gesting a role in cortical sculpting and plasticity. TLIS-associated CRADD variants do not disrupt interactions with caspase-2 or PIDD in
co-immunoprecipitation assays, but still abolish CRADD’s ability to activate caspase-2, resulting in reduced neuronal apoptosis in vitro.
Homozygous Cradd knockout mice display megalencephaly and seizures without obvious defects in cortical lamination, supporting a
role for CRADD/caspase-2 signaling in mammalian brain development. Megalencephaly and lissencephaly associated with defective
programmed cell death from loss of CRADD function in humans implicate reduced apoptosis as an important pathophysiological mech-
anism of cortical malformation. Our data suggest that CRADD/caspase-2 signaling is critical for normal gyration of the developing
human neocortex and for normal cognitive ability.
Introduction
Folding of the human cerebral cortex into its complex
pattern of gyri and sulci and the precise layering of neu-
rons within the cortex (cortical lamination) depend
upon a finely tuned program of neuronal proliferation,
migration, connectivity, and pruning.1–5 Lissencephaly
is a cortical malformation characterized by abnormally
broad or absent gyri with unusually thick cortex (10–
20 mm, normal range 1–4.5 mm6) that is classically
caused by deficient neuronal migration.7–10 From review
of phenotypes in more than 1,400 subjects with lissence-
phaly, we identified a relatively mild variant characterized
by anterior-predominant pachygyria with shallow and
unusually wide sulci, mildly thick cortex (5–7 mm) in at
least the frontal regions, and no non-cortical malforma-
tions in 13 families, a pattern we refer to as ‘‘thin’’ lissen-
cephaly (TLIS). Several families had multiple affected
siblings, indicative of autosomal-recessive inheritance.
Similar phenotypes have been reported a few times, but
with no underlying cause identified (MIM: 610279).11–14
We performed trio-based whole-exome sequencing in
two families with TLIS and detected a homozygous muta-
tion of CRADD (GenBank: NM_003805.3; c.382G>C
[p.Gly128Arg] [MIM: 603454]) in two siblings from a
Mennonite family. Targeted re-sequencing of an addi-
tional 18 unrelated individuals with TLIS identified
two other homozygous missense mutations in CRADD
(c.508C>T [p.Arg170Cys] and c.509G>A [p.Arg170His])
in families of Turkish and Finnish ancestry, respectively,
and a fourth missense change (c.491T>G [p.Phe164Cys])
in trans with a 3.07 Mb deletion of chromosome 12q22
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that includes CRADD in an affected child of a fourth
family.
CRADD encodes caspase-recruitment-domain and death
domain (DD)-containing protein (also known as RAIDD,
receptor-interacting protein-associated ICH-1/CED-3 ho-
mologous protein with a death domain), which is required
for activation of caspase-2-mediated apoptosis.15,16
In general, CRADD serves as an adaptor between
PIDD (p53-induced death domain-containing protein 1,
PIDD1 [MIM: 605247]) and caspase-2 (CASP2 [MIM:
600639]) during formation of the apoptosis-promoting
PIDDosome.15–18 Phosphorylation of PIDD by signaling
associated with cellular or genotoxic stress stimulates bind-
ing of the PIDD-DD to the CRADD-DD, which in turn al-
lows the caspase recruitment domain (CARD) of CRADD
tobind and activate caspase-2.15–20Dendritic spine collapse
and neuronal apoptosis induced by neurotrophic factor
withdrawal or amyloid-b aggregation can be initiated
by CRADD/caspase-2 signaling in the absence of PIDD,
suggesting that formation of the PIDDosome may not
be required for caspase-2-driven synaptic remodeling and
neuronal apoptosis.21,22
The caspases are intracellular proteases that maintain
homeostasis through regulation of inflammation (cas-
pase-1, -4, -5, -12) and apoptosis (caspase-2, -3, -6, -7, -8,
-9).4 During mammalian brain development, caspase-3
(CASP3 [MIM: 600636]) is the primary executioner of syn-
aptic and neuronal pruning and is activated by the mito-
chondrial (intrinsic) apoptotic cascade through APAF1
(apoptotic protease-activating factor 1 [MIM: 602233])/
caspase-9 (CASP9 [MIM: 602234]) activation.2,4,23,24
Although caspase-2 is expressed in neurons in the embry-
onic and adult mammalian brain,25–28 its role in brain
development has been elusive.4
Here we show that the human CRADD variants associ-
ated with TLIS abrogate CRADD’s ability to activate cas-
pase-2 and drive neuronal apoptosis. The megalencephaly,
lissencephaly variant, and intellectual disability associated
with loss of CRADD/caspase-2-mediated apoptosis imply a
role for CRADD/caspase-2 signaling in development of the
human cerebral cortex.
Subjects and Methods
Research Subjects
W.B.D. has ascertained ~1,400 children with lissencephaly or
subcortical band heterotopia over the last 30 years. Clinical infor-
mation and results of genetic testing were obtained from medical
records submitted together with MRI scans by referring physicians
or parents of the subjects. Genetic testing included results of chro-
mosome analysis, fluorescence in situ hybridization for deletion
17p13.3 (MIM: 247200), chromosome microarrays, MLPA for
LIS1 (PAFAH1B1 [MIM: 601545]) and DCX (MIM: 300121), Sanger
sequencing of single genes (LIS1, DCX, ARX [MIM: 300382],
TUBA1A [MIM: 602529], TUBB2B [MIM: 612850], RELN [MIM:
600514], VLDLR [MIM: 192977], ACTB [MIM: 102630], and
ACTG1 [MIM: 102560]), targeted gene panels, and whole-exome
sequencing. We re-reviewed scans of 188 subjects ascertained be-
tween 2009 and 2015, when high-resolution scans were available
for most individuals. All were reviewed with particular attention
to the severity and gradient of the gyral malformation, cortical
thickness, and presence of associated brain malformations.
Thin undulating LIS with normal cerebellum (TLIS) was seen in
9 of 188 subjects (5%). We also searched W.B.D.’s large research
database for subjects with frontal pachygyria and normal cere-
bellum and corpus callosum and identified 12 additional individ-
uals with the specific TLIS pattern. Several had large or relatively
large occipitofrontal circumference (OFC), which we subdivide
into true (OFC > 3 SD above the mean), mild (OFC 2–3 SD above
the mean), and relative (OFC more than 2 SD greater than height)
megalencephaly.29
Institutional review boards at The University of Chicago and
Seattle Children’s Hospital approved this study. Seven members
of an additional Mennonite family carrying CRADD c.382G>C
and receivingmedical care at the Clinic for Special Children (Stras-
burg, PA) were added to the study (see Results). Their participation
was approved by the Institutional Review Board at Lancaster Gen-
eral Hospital. Informed consent signed by the parents or legal
guardians was obtained for all participating individuals.
Whole-Exome Sequencing
Exome capture and sequencingwere done using Agilent SureSelect
Human All Exon V5 enrichment and Illumina HiSeq 2500
sequencing (paired-end 2 3 100 nt). The sequencing data were
processed using CLC Biomedical GenomicsWorkbench (QIAGEN)
including read alignment to UCSCGenome Browser hg19, variant
calling (SNPs and indels), annotation, and filtering against three
public databases (ExAC, dbSNP, and 1000 Genomes Project). For
each sample, the average coverage through the exome was 80-
fold and more than 90% of the exome was covered at least 20-
fold.We focused on protein-altering and splice-site variants absent
in databases or present with allele frequencies below 0.01. We
filtered variants to systematically identify homozygous variants
that were heterozygous in both parents, compound-heterozygous
variants inherited from one parent, as well as de novo variants.
Targeted Panel Sequencing with Single-Molecule
Molecular Inversion Probe
Using an established MIPGEN pipeline,30 we designed a pool of
673 single-moleculemolecular inversion probes (smMIP) targeting
the coding regions of 16 known LIS-associated genes—ACTB,
ACTG1, ARX, DCX, DYNC1H1 (MIM: 600112), KIF2A (MIM:
602591), KIF5C (MIM: 604593), LIS1, RELN, TUBA1A, TUBA8
(MIM: 605742), TUBB (MIM: 191130), TUBB2B (MIM: 612850),
TUBB3 (MIM: 602661), TUBG1 (MIM: 191135), and VLDLR—
and our candidate gene,CRADD. In total, smMIPs were tiled across
47,975 bp of coding sequence. Capture reactions (100 ng) were
performed in parallel using previously published protocols.30,31
Massively parallel sequencing was done on the Illumina HiSeq
and MiSeq platforms. The average collapsed coverage (number
of single-molecule consensus sequences or ‘‘smc-reads’’)31 across
all samples was 21.
Cradd Knockout Mice
Cradd/ mice on a C57BL/6 background were obtained from
the Jackson Laboratories with permission from Prof. Tak Mak
(University of Toronto).17 Wild-type (WT) C57BL/6 mice were
also obtained from the Jackson Laboratories and all mice were
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maintained under pathogen-free conditions. All animal experi-
ments were approved by the Institutional Animal Care and Use
Committees (IACUC) of Franklin & Marshall College and
Columbia University Medical Center.
Whole-Animal Perfusion Fixation
Transcardial perfusion fixation was used to prepare mouse heads/
brains (as described elsewhere32) for micro-CT and histological
analyses. In brief, mice were anesthetized by intraperitoneal
(i.p.) injection of ketamine/xylazine mixture (up to 80 mg/kg
body weight ketamine and 10 mg/kg body weight xylazine).
When a surgical plane of anesthesia was achieved, the heart was
exposed, a 23G cannula inserted into the ascending aorta via the
left ventricle, and a perfusate exit hole placed in the right atrium.
The circulation was slowly flushed with 20–30 mL of phosphate
buffered saline (PBS; pH 7.4) followed by perfusion of 30–40 mL
of 0.22 mm sterile-filtered, freshly prepared 4% paraformaldehyde
in PBS. Upon complete blanching of the liver andmesentery, mice
were decapitated and intact skulls and brains were postfixed over-
night in 4% paraformaldehyde in PBS at 4C.
Cortical/Brain Histology
Dissected brains were infiltrated with 30% sucrose in PBS,
embedded in optimum cutting temperature (OCT) compound,
and sectioned at 20 mm on a cryostat. Every 10th section was
placed on a slide and stained in 0.1% cresyl violet solution for
10 min, rinsed quickly in PBS, dehydrated in 95% ethanol, and
left in xylene before being coverslipped with Permount (Fisher
Scientific). Brightfield images were taken using a Leica MZFLIII
microscope with a Leica DFC425 camera and LAS V3.8 software.
Volumetric Mouse Skull CT
A total of 17 skulls were imaged at the Small Animal Tomographic
Analysis Lab at Seattle Children’s Research Institute using a
Skyscan 1076C microtomograph (Bruker) with settings optimized
for mouse skulls (voltage, 55 kV; current, 180 mA; 0.5 mm Al filter;
100 ms exposure; 0.6 rotation steps; three frames averaged per
rotation; 360 degree full rotation). Scan duration was approxi-
mately 10 min per sample. 600 shadow images were acquired
per specimen, which were reconstructed as image stacks at
34.42-micron resolution using the manufacturer’s proprietary
software. All reconstructed image stacks were brought into stan-
dardized anatomical orientation using Dataviewer (Bruker) and
converted to NIfTI volumetric format to be loaded into 3D Slicer
to visualize the skull morphology. Skull measurements were also
taken using 3D Slicer.33 Soft tissue, such as brain, cannot be effec-
tively imaged via micro-CT. Instead, we chose to look at the en-
docranial volume, which is tightly correlated with brain size.
Although segmenting the endocranial space using automated
watershed algorithms from the skull is straightforward, it requires
all cranial openings to be sealed digitally, so that segmentation
does not leak into other regions. To reduce the amount of manual
segmentation and avoid rater bias on measurements, we chose to
construct an unbiased atlas of our study population, segment the
endocranial space, and warp it back to the constituent samples us-
ing deformable registration. We used the open-source DRAMMS
deformable registration software and atlas-building pipeline in
this study.34,35 The DRAMMS registration software consists of
two major components: attribute matching and mutual-saliency
weighting. Attribute matching characterizes each voxel by a
high dimensional vector of multi-scale and multi-orientation Ga-
bor attributes. This method provides more information than the
intensity information traditionally used (see Developmental Brain
ADC Atlas in Web Resources).34–37 Because the reliability and
accessibly of correspondence varies across anatomical structures,
mutual-saliency upweights regions of the volume where corre-
spondence can be reliably established between the source and
target images. The preferred use of reliable correspondence reduces
the negative impact of outlier regions on the registration quality
(see Developmental Brain ADC Atlas in Web Resources).34–37 Atlas
construction was performed using the DRAMMS deformable regis-
tration in a classic unbiased population registration framework.37
The atlas construction framework iteratively finds a virtual space
that resides in the centroid of the study population (centroid
meaning that the deformations needed to transform all subjects
into this virtual space sum up to zero everywhere in this virtual
space). Therefore, the constructed atlas is unbiased to any subject
in the population and is hence representative of the mean anat-
omy/geometry of the population (see Developmental Brain ADC
Atlas in Web Resources).37 The constructed atlas was segmented
using the editor module of 3D Slicer. This reference segmentation
was then mapped onto the individual samples by inversing their
transformation into the atlas (Figure S7). Individual volumes of
endocranial space were calculated after this transformation and
are reported in Table S2.
cDNA Cloning and Mutagenesis
Full-length human CRADD coding cDNA (GenBank: NM_003805.
3) and the coding sequence for the PIDD death domain (PIDD-
DD) (PIDD1 [GenBank: NM_145886.3]) were amplified by PCR
from cDNA reverse transcribed from human ARPE-19 cell mRNA
using Moloney Murine Leukemia Virus (M-MuLV) reverse tran-
scriptase (NEB). PCR products were ligated into pENTR/D-
TOPO (ThermoFisher), and CRADD TLIS mutations (c.382G>C,
c.491T>G, c.508C>T, c.509G>A) were introduced with site-
directed mutagenesis (QuikChange II, Agilent Technologies). LR
recombination (LR Clonase II, ThermoFisher) was used to
generate FLAG (pCAGIG/RFC-A/N-FLAG) or V5 (pcDNA3.1/N-
V5) mammalian expression plasmids from pENTR clones. All
clones were verified with Sanger sequencing.
Transduction of Pen1-CRADD
CRADD cDNAs—WT and CRADD TLIS variants described above—
were subcloned into the Novagen pET15b expression system in-
frame with an N/C-terminal polyhistidine sequence downstream
of the T7 promoter and expressed in BL21 cells that express the
T7 RNA polymerase under an IPTG-inducible promoter. The
expressed proteins were purified on a Ni2þ resin as previously
described.38 Penetratin 1 (Pen1) was mixed at a 2:1 molar ratio
with purified CRADD and incubated 2 hr at 37C to generate disul-
fide-linked Pen1-CRADD. Linkage was assessed by 20% SDS-PAGE
and by western blotting with anti-His antibody and anti-CRADD
antibody as previously described.39 To ensure uniform protein
transduction across cultures, Pen1-CRADD was used at the same
concentration (27 nM). PC12 cells and mouse sympathetic
neurons take up Pen1 proteins with near 100% efficiency. This
approach is more efficient, less cytotoxic, and easier to titrate
than transient transfection of cDNA constructs.40,41
Cell Lines and Transfection
ARPE-19, HEK293T, and Neuro2a cells used in this study were
purchased from the American Type Culture Collection (ATCC).
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ARPE-19 cells were cultured in DMEM:F12 with 10% fetal bovine
serum (FBS), and HEK293T and Neuro2a were cultured in DMEM
with 10% FBS. Cells were transfected with FuGENE 6 (Roche) at
a 3:1 FuGENE6:DNA ratio according to the manufacturer’s instruc-
tions. Primary cultures of dermal fibroblasts from skin biopsies
from CRADD TLIS-affected individuals (homozygous c.382G>C
[p.Gly128Arg]) and their heterozygous parents were established
by the Coriell Institute, and normal human dermal fibroblasts
were acquired from Coriell. Fibroblasts were cultured at low pas-
sage (%10) in DMEM with 10% FBS. Unless otherwise noted, all
cells were maintained at 37C and 5% CO2. To assess CRADD
abundance in subject fibroblasts, cells were lysed in RIPA buffer
(50 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate,
0.1% SDS, 50mMTris [pH 8.0] [Sigma]) containing protease inhib-
itor cocktail (Roche), phosphatase inhibitor (PhosSTOP, Roche),
and 1 mM phenylmethylsulfonyl fluoride (PMSF) for 15 min at
4C. Total protein concentration was normalized across affected
subject, heterozygous parents, and normal fibroblast samples
using the Bradford assay (Bio-Rad), and equal protein loading
for immunoblotting was confirmed with mouse monoclonal
anti-b-actin labeling (Sigma, 1:1,000,000). CRADD abundance
was assessed with rabbit monoclonal anti-human RAIDD anti-
bodies (Abcam cat# ab52621 and ab76465, RRID: AB_882269
and AB_1524296; 1:1,000). Goat anti-mouse IgG-HRP (Cell
Signaling, 1:1,500) and goat anti-rabbit IgG-HRP (Cell Signaling,
1:1,500) were used as secondary antibodies. Blots were imaged
with enhanced chemiluminescence using SignalFire Plus (Cell
Signaling).
PC12 Cell Culture and Viability
PC12 cells obtained from the ATCC were grown as described pre-
viously21 at 7.5% CO2 on rat-tail collagen-coated dishes in RPMI
1640 medium (Life Sciences) containing 1% penicillin/strepto-
mycin (P/S), 5% fetal calf serum (FCS), and 10% heat-inactivated
horse serum (HS, completemedium). PC12 cell survival was scored
as reported previously.42 Culture medium was removed by aspira-
tion and 100 mL of detergent-containing lysis solution was added
to the well. This solution dissolves cell membranes, providing
a suspension of intact nuclei that were quantified using a hemocy-
tometer. Triplicate wells were scored and values reported as mean
5 SEM. Significance was calculated by Student’s t test.
Primary Sympathetic Neuron Culture and Viability
Neurons were cultured as described previously.22,43 In brief,
sympathetic neurons were dissected from 1-day-old WT and
CRADD-null17 (Cradd/) mouse pups. Cultures were maintained
in RPMI 1640 medium supplemented with 10% horse serum
and mouse nerve growth factor (NGF; 100 ng/ml) on collagen-
coated 24-well dishes. At 1 day after plating, uridine (10 mM)
and 5-fluorodeoxyuridine (10 mM) were added for 3 days to elimi-
nate non-neuronal cells. Experiments were conducted after 6 days
of culture. Viability was determined as previously reported.22 Each
culture was scored as numbers of living phase-bright neurons
counted in the same field at various times. Three replicate cultures
were assessed for each condition; data were normalized to the
number of neurons present in each culture at the time of Pen1-
CRADD treatment and are reported as means5 SEM.
Immunofluorescence Microscopy
Cells cultured on uncoated German glass coverslips transfected
with pCAG/FLAG-CRADD WT or CRADD-TLIS variant cDNAs
were rinsed with PBS at 37C and fixed with 4% paraformaldehyde
at 21C for 15 min. Cells were then prepared for immunofluores-
cence microscopy and documented as described previously.44
The primary and secondary antibodies used were anti-FLAG
M2 (Sigma, 1:1,000) and Alexa Fluor 488-goat anti-mouse IgG1
(ThermoFisher, 1:400), respectively. Nuclei were stained with
1 mg/mL DAPI (Santa Cruz Biotechnology), and coverslips were
mounted with Fluoromount-G (Electron Microscopy Sciences).
CRADD and PIDD Co-immunoprecipitation
Co-immunoprecipitation was performed as described previ-
ously.44,45 In brief, pCAG/FLAG-CRADD WT and CRADD-
TLIS variant cDNAs or empty vector were co-transfected with
pcDNA3.1/V5-PIDD1-DD cDNA in Neuro2a and HEK293T cells
for 40–48 hr, after whichwhole-cell lysates were clarified by centri-
fugation at 14,000 rpm for 15 min and incubated with anti-FLAG
M2 affinity resin (Sigma) for 2 hr with end-over-end mixing at
4C. Resin beads were pelleted and washed 33 in Tris-buffered
saline (pH 7.2) with protease inhibitor cocktail (Roche), phospha-
tase inhibitor (PhosSTOP, Roche), 1 mM PMSF, and 0.5%–1%
Tween-20, before elution with 150 ng/mL 3x-FLAG peptide
(Sigma). Input lysates and eluates were denatured in sample buffer
at 100C for 10 min and then immunoblotted with anti-FLAG
(Sigma, 1:1,000) and anti-V5 (ThermoFisher, 1:5,000) antibodies.
Caspase-2 and CRADD Co-immunoprecipitation
Mouse IgG or rabbit IgG magnetic beads (Invitrogen) were pre-
coated with affinity-purified anti-caspase-2 antibody42 for 2 hr at
4C on a rotator. In total, 10 mL of anti-caspase-2 antibody was
used per 30 mL of beads. PC12 cells were transduced with Pen1-
CRADD for 5 hr. Cell lysates were prepared using CHAPS lysis
buffer (150mMKCl, 50mMHEPES, 0.1%CHAPS, and protease in-
hibitor cocktail [pH 7.4]).22 Lysates (70–120 mg) were loaded onto
anti-caspase-2 antibody pre-coated beads and incubated overnight
at 4C on a rotator. After overnight incubation, the captured pro-
teins were boiled off the beads at 100C for 5 min. The immuno-
precipitated samples, along with inputs, were then subjected
to western blot analysis using an anti-CRADD antibody (Abnova),
an anti-caspase-2 antibody (Alexis), or an anti-ERK antibody
(Santa Cruz Biotechnology). Proteins were detected using the
Odyssey Infrared Imaging System (LI-COR Biosciences).
Caspase-2 Activity Assay
We adapted an unbiased caspase-2 activity measurement from
Jean et al.43 bVAD-fmk (biotin-Val-Ala-DL-Asp-fluoromethylke-
tone; 50 mM, MP Biomedicals), a biotinylated pan-caspase inhibi-
tor that traps active caspases, was added to PC12 cultures 1 hr prior
to treatment with Pen1-CRADD. Cells were lysed in CHAPS buffer.
Active caspase-bVAD-fmk complexes were pulled out with strepta-
vidin-coated beads (Invitrogen). Active caspase-2 was detected by
western blotting using affinity-purified polyclonal anti-caspase-2
antibody.42
Results
Clinical Presentation and Molecular Genetic Analysis
of CRADD-Associated Lissencephaly
Review of brain neuroimaging from more than 1,400
subjects with lissencephaly revealed a relatively mild
lissencephaly variant characterized by megalencephaly,
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anterior-predominant pachygyria with shallow and un-
usually wide sulci, mildly thick cortex (5–7 mm) especially
in the frontal regions (TLIS), and no non-cortical malfor-
mations in 13 families (Figures 1, S1, and S2). Pedigree
analysis suggested autosomal-recessive inheritance. Trio-
based whole-exome sequencing (WES) in two families
with TLIS detected a homozygous mutation of CRADD
(GenBank: NM_003805.3; c.382G>C [p.Gly128Arg]) in
two siblings from a Mennonite family that segregated in
the parents.
To identify additional mutations, we performed Sanger
sequencing of the two coding exons of CRADD in another
18 subjects with TLIS and detected homozygous missense
mutations in two affected siblings born to consanguineous
Turkish parents (c.508C>T [p.Arg170Cys]) and a pro-
band with Finnish ancestry (c.509G>A [p.Arg170His]),
as well as a single variant (c.491T>G [p.Phe164Cys])
in an American boy of Western European background
(Table 1). Notably, we previously detected a 3.07 Mb
deletion of chromosome 12q22 (chr12: 92,443,579–
95,515,465; hg38) in this boy that includes the remaining
CRADD allele.46 Targeted panel sequencing in another 148
LIS-affected subjects for whom molecular genetic testing
did not detect mutations in any of the known LIS-associ-
ated genes did not reveal additional CRADD mutations.
The four CRADD mutations identified in six individ-
uals from four unrelated families with different ethnic
backgrounds are all rare variants (ExAC allele frequency
< 0.0005) with high pathogenicity scores (Table 1)
that alter highly conserved residues within the CRADD
death domain (Figure 2A). The first CRADD mutation
(c.382G>C [p.Gly128Arg]) that we identified was previ-
ously reported in another large family with multiple
members presenting with mild to moderate ID;44 both
families belong to the Mennonite (Plain) population of
Pennsylvania. The prior family was added to the study,
and brain MRI performed in three of seven affected indi-
viduals revealed TLIS with normal cerebellum, in line
with the MRI features in all other CRADD-TLIS-affected
subjects.
Brain imaging and additional clinical data for all
affected individuals are shown in Figures 1 and S2 and
summarized in Table S1 and Figure S1. Case reports are
provided in the Supplemental Data. Of 13 CRADD-TLIS-
affected subjects, 9 (69%) had mild intellectual disability
(ID), while three had mild to moderate ID and one had
borderline ID (IQ ¼ 70–75). Seizures (3 of 13) and addi-
tional abnormalities such as hydrocephalus due to Chiari
malformation (MIM: 118420) were associated with lower
cognitive function. None of the CRADD-TLIS-affected
subjects had congenital anomalies other than TLIS,
and all were in good general health. Clinical course of
the TLIS-affected subjects without CRADD mutations
was similar to the CRADD-associated group. However,
all TLIS-affected individuals without CRADD mutations
had either normal or small head size. In summary, indi-
viduals with recessive CRADD mutations (n ¼ 13) pre-
sented with TLIS, mild to moderate ID, epilepsy (3 of
13), and either enlarged head size with occipitofrontal
circumference (OFC) 2–3 SD (mild megalencephaly in 9
of 13) or true megalencephaly with OFC > 3 SD (2 of
13). One individual had relative megalencephaly, and 1
of the 13 TLIS-affected individuals studied did not have
megalencephaly (Table S1).
Figure 1. Brain Imaging of TLIS-Affected
Individuals with CRADD Mutations
(A–D)MRI in subject LR04-101a1 at 5 years
shows normal brainstem and cerebellum
(A, B), frontal predominant symmetric pa-
chygyria with reduced number of gyri,
shallow sulci, and mildly thickened cortex
(double arrowheads in B, C, and D with ar-
rowheads located only in the left hemi-
sphere).
(E–H)MRI in subject LR05-279a2 at 7 years
demonstrates the same pattern as in the
top row (double arrowheads in F, G, and
H). The enlargement in the inferior cere-
bellum is a mild Chiari malformation
type I (asterisk in E).
(I–L) Age-matched normal control images.
The cortex in TLIS-affected individuals is
mildly thick, measuring 5–7 mm in the
frontal lobes (see C and G) compared to
normal cortex, measuring 3–4 mm (inset
in K).
MRI image section planes: A, B, E, F, I, J,
sagittal T1-weighted images; C, G, K, axial
T1-weighted images; D, H, L, coronal T2-
weighted images.
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TLIS Variants Cluster in the CRADD Death Domain
In response to intrinsic death signals (e.g., genotoxic
stress or neurotrophic factor withdrawal), the C-terminal
CRADD-DD interacts with the PIDD-DD to form the
PIDDosomeenabling theN-terminalCRADDCARDdomain
to interact with and activate caspase-2.17,18 TLIS-associated
CRADD variants (p.Gly128Arg, p.Phe164Cys, p.Arg170Cys,
and p.Arg170His) cluster in the DD (Figure 2A), suggesting
that they may disrupt interaction with the PIDD-DD.
TLIS CRADD Variants Do Not Disrupt Binding with
PIDD or Caspase-2
To determine the functional impact of the TLIS-CRADD
death domain mutations, we first investigated binding of
the CRADD variants to PIDD and caspase-2 and then
assessed their ability to induce apoptosis by activating
caspase-2. Ultimately, these experiments showed that
TLIS-CRADD variants fail to drive caspase-2-initiated
apoptosis without significant loss of binding to either
PIDD or caspase-2.
In human cells, exogenously expressed p.Gly128Arg
CRADD is present at very low abundance, indicating
decreased protein stability relative to wild-type (WT)
CRADD (Figure 2B). Additionally, it forms abnormal
cytosolic clusters (Figure S3) and fails to interact with
PIDD in vitro18,44 (Figure 2D). Dermal fibroblasts from
p.Gly128Arg CRADD TLIS-affected subjects are essentially
null for CRADD abundance (Figure 2C) relative to hetero-
zygous parent and normal human dermal fibroblasts.
Fibroblasts were not available from other CRADD TLIS-
affected individuals. However, recombinant p.Phe164Cys,
p.Arg170Cys, and p.Arg170His CRADD overexpressed in
human cells (ARPE-19, HEK293T) and mouse neuroblasts
(Neuro2a) displayed protein abundance and cellular
localization comparable to that observed for WT CRADD
(Figures 2B and S3), suggesting that the reduced protein
abundance observed for p.Gly128Arg CRADD is not a
primary pathogenic mechanism in TLIS.
Because the TLIS-CRADD mutations cluster in the DD
(Figure 2A) where CRADD and PIDD interact,18 we investi-
gated whether the CRADD variants disrupted interaction
with PIDD (PIDD-DD) as we observed for p.Gly128Arg
CRADD.44 Immunoprecipitation of recombinant FLAG-
CRADD overexpressed in Neuro2a (data not shown)
and HEK293T cells co-precipitated V5-PIDD-DD for
each of the CRADD-TLIS variants except p.Gly128Arg
(Figure 2D). These data suggest a pathophysiological mech-
anism other than disrupted PIDD interaction, consistent
with our protein structural modeling (see Figure S4 and
Discussion) and with the earlier finding that neuronal
caspase-2 activation requires CRADD expression but can
occur independent of PIDD expression.22
Upon activation, the N-terminal caspase-recruitment
domain (CARD) of CRADD (Figure 2A) binds with cas-
pase-2 to induce caspase-2 activity.15,16 To determine
whether CRADD-TLIS variants can activate caspase-2, we
first determined whether they could bind to caspase-2. ToTa
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efficiently deliver CRADD-TLIS variant proteins into cells
without the cytotoxic side effects of transient transfection,
CRADD-TLIS protein variants were directly linked to Pene-
tratin-1 (Pen1) by a disulfide bond. Pen1 facilitates high-
efficiency cellular uptake of linked proteins, and the
reducing environment of the cytosol then cleaves the
disulfide linkage releasing the transported protein.40,41
PC12 cells were transduced with Pen1-linked constructs
of each of the CRADD-TLIS variants and caspase-2
was immunoprecipitated from whole-cell lysates 5 hr
after transduction. Immunoprecipitated caspase-2 pulled
down each of the CRADD-TLIS variants, suggesting that
all of the CRADD-TLIS variants can interact with caspase-2
when the blots are normalized for CRADD abundance
(Figures 2E and 2F).
TLIS Variants Disrupt CRADD’s Ability to Drive
Neuronal Apoptosis
One parsimonious explanation for TLIS could be that
loss of CRADD function results in reduction of
A
B C
D
F
E
Figure 2. TLIS CRADD Variants Do Not
Disrupt Binding with PIDD or Caspase-2
(A) Functional domain structure of CRADD
showing TLIS substitutions clustered in
the C-terminal death domain (DD, amino
acids 116–188). CARD, N-terminal cas-
pase-recruitment domain (amino acids
1–91). CRADD substitutions p.Gly128Arg,
p.Arg170Cys, and p.Arg170His are ho-
mozygous in individuals with TLIS. The
p.Phe164Cys encoding CRADD allele
(c.491T>G) is in trans with a 3.07 Mb dele-
tion of chromosome 12q22 (denoted by
the two redXs) in one TLIS-affected subject
(see Table 1).
(B) Immunoblot (IB) of recombinant
FLAG-CRADD TLIS variants overexpressed
in HEK293T cells (n ¼ 6). NTC, non-trans-
fected control. Receptor-interacting serine/
threonine-protein kinase 1 (RIPK1 [MIM:
603453]; 78 kDa) immunoblotting was
used as a loading control.
(C) Top: western blot of CRADD (23 kDa)
from dermal fibroblasts of a TLIS-affected
subject homozygous for p.Gly128Arg
CRADD (p.Gly128Arg/p.Gly128Arg) versus
heterozygous parent (WT/p.Gly128Arg)
and normal human dermal fibroblasts
(WT/WT) (n ¼ 4). Anti-b-actin (42 kDa)
immunoblotting was used as a loading
control. Bottom: Reverse transcriptase-
PCR of the full-length human CRADD cod-
ing sequence (GenBank: NM_003805.3;
658 bp) from CRADD p.Gly128Arg
(c.382G>C) TLIS-affected subject dermal
fibroblasts (p.Gly128Arg/p.Gly128Arg)
versus heterozygous parent (WT/
p.Gly128Arg) and normal fibroblasts (WT/
WT) demonstrating stability of the mutant
transcript. Note: the WT/WT lane of the
RT-PCR gel was cropped from the same gel
usedfor thesubject andheterozygousparent
samples. Cropping is denoted by the white
bar separating lanes 2 and 3.
(D) FLAG-CRADD WT and TLIS variants
were co-overexpressed with V5-PIDD-DD
in HEK293T cells (as indicated) for 40 hr
after which FLAG-CRADDwas immunopre-
cipitated (IP) from whole cell lysates (input)
with anti-FLAGM2affinity resin.Co-precip-
itated complexes were first immunoblotted (IB) with anti-V5 antibody (PIDD-DD). Blots were then stripped and reprobed with anti-FLAG
antibody (CRADD). CRADDWTand each of the TLIS CRADD variants except for p.Gly128Arg CRADD co-precipitated PIDD-DD (n¼ 3).
(E and F) Immunoprecipitation (IP) of caspase-2 from PC12 cells 5 hr after the cells were transducedwith 27 nMPen1-CRADDproteins as
indicated (n ¼ 2–3). Caspase-2 co-precipitated Pen1-CRADD WT and TLIS variants in similar abundances when corrected for Pen1-
CRADD abundance in whole cell lysates (input) as shown in (F). Blots were stripped and reprobed with anti-caspase-2. Error bars repre-
sent SEM. NS, no significant difference; control, non-transduced cells. ERK immunoblotting was used as an input lysate loading control.
CRADD p.Gly128Arg abundance is always lower in transduced PC12 cells, in agreement with our previous findings.44
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caspase-2-mediated apoptosis, resulting in megalence-
phaly and TLIS from failure to prune inappropriate neu-
rons and/or neuropil. Overexpression of WT CRADD in
PC12 and other mammalian cells (e.g., HEK293) is suffi-
cient to activate caspase-2 and promote apoptosis.15,47 To
examine whether CRADD-TLIS variants fail to induce
apoptosis, PC12 cells were transduced with Pen1-linked
human WT and CRADD-TLIS variants and cell survival
was measured 1 day after treatment. Only WT CRADD
import induced apoptosis in PC12 cells. Transduc-
tion of PC12 cells with Pen1-linked CRADD-TLIS vari-
ants (p.Gly128Arg, p.Phe164Cys, p.Arg170Cys, and
p.Arg170His) failed to induce cell death (Figure 3A). To
confirm this finding in neurons lacking endogenous
CRADD, primary sympathetic neurons from Cradd
knockout (Cradd/) mice were transduced with Pen1-
linked human WT and p.Gly128Arg CRADD. CRADD WT
resulted in significant cell death of primary sympathetic
neurons from Cradd/ mice 1 day after transduction,
whereas cell survival after transduction of p.Gly128Arg
CRADD was indistinguishable from that of non-trans-
duced cells (Figure 3B).
CRADD TLIS Variants Do Not Activate Caspase-2
All CRADD-TLIS variants bind to caspase-2 but only WT
CRADD induces cell death, so we next determinedwhether
CRADD-TLIS variants can induce caspase-2 activation. To
measure caspase-2 activity, we used the caspase-affinity
Figure 3. TLIS-CRADD Variants Fail to
Activate Caspase-2-Initiated Apoptosis
(A and B) Pen1-CRADDWT (27 nM) drives
apoptosis 1 day after transduction in PC12
cells (A) and in primary sympathetic
neurons from Cradd/ mice (B) whereas
Pen1-TLIS-CRADD variants (27 nM) do
not (n ¼ 4 for each cell type). Control
indicates non-transduced cells.
(C) TLIS-CRADD variants fail to activate
caspase-2. PC12 cells were treated with
50 mM bVAD-fmk for 1 hr followed by
transduction with 27 nM Pen1-CRADD as
indicated for 2 hr. Caspase-bVAD-fmk
complexes in whole-cell lysates were
precipitated with streptavidin and immu-
noblotted for caspase-2. Precipitated cas-
pase-2 band optical density was used as a
measure of relative caspase-2 activity42,43
(n ¼ 3). Error bars represent SEM. Control
indicates non-transduced cells.
ligand biotin-Val-Ala-DL-Asp-fluoro-
methylketone (bVAD-fmk), a pan-cas-
pase substrate/inhibitor that binds to
the first active caspase, and which
we previously showed is effective in
measuring caspase-2 activity in PC12
cells.42,43 PC12 cells were treated
with bVAD-fmk for 1 hr prior to trans-
duction with Pen1-CRADD WT and
TLIS variants. Two hours after transduction, cells were har-
vested for streptavidin pulldown of bVAD-fmk:caspase
complexes followed by western blotting for caspase-2
(Figure 3C). We found that only WT CRADD induces cas-
pase-2 activity; the CRADD-TLIS variants do not. This sug-
gests that although the CRADD-TLIS variants can bind
caspase-2, they are unable to activate caspase-2 and induce
apoptosis. In sum, in vitro experiments demonstrated
functional defects in caspase-2 activation despite no
consistent defects in protein interactions with PIDD or
caspase-2.
Cradd Knockout Mice Display Megalencephaly and
Seizures Consistent with TLIS
To determine whether loss of CRADD function results
in a TLIS-like phenotype in mice, we analyzed cortical
morphology and head size in Cradd/ mice. The Cradd/
miceusedwere previously reported tohavenormal develop-
ment, although brain morphology and head size were not
studied.17 Volumetric micro-CT skull analysis of Cradd/
mice relative to heterozygous (Craddþ/) and WT controls
demonstrated that all mutantmice had a statistically signif-
icant increase in endocast volume that corresponds to
increased brain volume (Figure 4). Morphological analysis
of Cradd/ cortex revealed normal layering indistinguish-
able from WT mice (Figure S5). Notably, 8 of 31 (26%)
Cradd/ mice displayed handling-induced seizures; no
WTor Craddþ/ littermates (0 of 60) had seizures.
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Megalencephaly with normal cortical morphology in
Cradd/ mice coupled with loss of function in driving
apoptosis through caspase-2 activation in the CRADD-
TLIS variants in vitro suggest that the cortical malforma-
tion in CRADD-TLIS more likely results from reduced
caspase-2-mediated apoptosis during cortical development
than a neuronal migration disorder.
Discussion
CRADD/Caspase-2-Driven Apoptosis Is Required for
Normal Development of Neocortex
Here, we describe a mild ‘‘thin’’ lissencephaly (TLIS) result-
ing from loss of CRADD function and reduced caspase-2-
initiated neuronal apoptosis. Recent reviews have postu-
lated that decreased apoptosis could underlie some human
brain overgrowth disorders (e.g., megalencephaly).48 How-
ever, to date no human cortical malformations associated
with decreased apoptosis have been reported. The poten-
tial impact of reduced apoptosis during mammalian brain
development was previously demonstrated by brain mal-
formations in caspase-3-,49 caspase-9-,50,51 and Apaf1-52
deficient mouse embryos and by increased forebrain size
in EphA7/ mice53 resulting from decreased apoptosis of
cortical progenitor cells. In contrast to the pachygyria
and mildly thick cortex associated with TLIS in humans,
caspase-3 (Casp3), caspase-9 (Casp9), and Apaf1 (Apaf1)
knockout mice displayed neural tube closure defects, fore-
brain protrusions of ectopic masses of cortical tissue that
deformed the anterior skull, and widespread increased
cell density from decreased apoptosis of progenitor cells
throughout the brain including the cortex, cerebellum,
and brainstem. Overgrowth of progenitors in these mice
is thought to result largely from loss of apoptosis of
morphogen-producing cells early in development (e.g.,
FGF8), altering the spatiotemporal morphogen gradients
that regulate progenitor expansion and ensure proper
forebrain development.54 During zebrafish development,
excessive activation of CRADD/caspase-2 signaling
through persistent phosphomimetic activation of Pidd
(pidd1) resulted in a severe microcephaly phenotype.19
TLIS CRADD Variants Fail to Activate Caspase-2-
Initiated Apoptosis without Disrupting Interaction
between CRADD and PIDD
The recent published structure of the PIDDosome in
solution suggests that the PIDDosome core is composed
of a CRADD-DD:PIDD-DD stoichiometry of 5:5 with 1–2
additional loosely associated CRADD-DDs.55 The solu-
tion structure suggests that the amino acids altered by
TLIS CRADD mutations do not participate in intra- or
inter-molecular interactions that are critical to the core
structure of the PIDDosome, and as such should not
alter caspase-2 activation through disrupted CRADD-
DD:PIDD-DD interaction. To explore this further, we
generated three protein models including the CRADD-
TLIS substitutions using SWISS-MODEL, IRECS, and
PyMOL (Figure S4). Based on ourmodels and the published
data, CRADD Arg170 forms a hydrogen bond with Glu188
on another CRADD-DD, while the adjacent amino acid
Ala169 interacts either with Val189 on another CRADD-
DD or Arg862 and Arg864 on a PIDD-DD (Figure S4).
The substitution of CRADD Arg170 to Cys or His should
inhibit hydrogen bond formation with Glu188. How-
ever, others recently determined that the 5:5 CRADD-
DD:PIDD-DD PIDDosome core is not disrupted by substi-
tution of CRADD Glu188 with Lys and that Glu188 is
solvent accessible in the core PIDDosome molecule in
solution. This suggests that Arg170 interaction with
Glu188 is not fundamentally important to formation of
the PIDDosome.55 Our models also predicted that Gly128
and Phe164 do not participate in an interaction interface
and should therefore have no direct contact with any
residues of the PIDD-DD (Figure S4).
Our co-immunoprecipitation data showing that all
FLAG-CRADD TLIS variants except for p.Gly128Arg
CRADD co-precipitate V5-PIDD-DD at abundances similar
to FLAG-CRADD WT support the modeling data which
suggest that TLIS-associated pathophysiology does not
result from impaired CRADD-DD:PIDD-DD interac-
tions. Previous in vitro mutational analysis suggested
that p.Arg170Ala-substituted CRADD exhibited a domi-
nant-negative effect interfering with formation of the
PIDDosome core by disrupting the interaction be-
tween CRADD and PIDD death domains.56 However,
p.Arg170His and p.Arg170Cys CRADD co-precipitated
PIDD-DD at abundances comparable to those co-precipi-
tated by wild-type CRADD in our experiments (Figure 2D).
Further, adult CRADD p.Arg170His and p.Arg170Cys het-
erozygotes had no symptoms suggestive of impaired
CRADD function, including no unusual sensitivity to gen-
otoxic stress. This suggests that the recent resolution of the
structure of the PIDDosome in solution55 provides a more
physiologically relevant model consistent with our data.
Figure 4. Megalencephaly in Cradd/ Knockout Mice
(A) Boxplot showing the ratio of endocranial volume to body
weight in Cradd control (heterozygous and wild-type, Het-WT)
(n ¼ 9) and Cradd/ knockout (Hom) (n ¼ 8) mice.
(B) Boxplot demonstrating the ratio of endocranial volume to hu-
merus surface area in Cradd control (Het-WT) (n¼ 5) and Cradd/
(Hom) (n ¼ 3) mice. Wild-type and heterozygous mice are shown
with closed and open circles, respectively.
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The lack of significant phenotypic differences between
TLIS-affected individuals homozygous for p.Gly128Arg
CRADD that disrupts interaction with the PIDD-DD versus
TLIS-affected individuals with CRADD variants that do
not disrupt PIDD-DD binding suggests that activation of
caspase-2 may be the only function of the PIDDosome dur-
ing brain development. Alternatively, formation of the
PIDDosome may not be required for neuronal apoptosis
during brain development. Amyloid-b-induced, CRADD/
caspase-2-initiated neuronal apoptosis persists in rat hip-
pocampal neurons depleted of PIDD and NGF withdrawal
induces CRADD/caspase-2 driven death of PIDD-null
(Pidd1/) mouse sympathetic neurons.22
The TLIS Phenotype Is Present but Less Pronounced in
Cradd Knockout Mice
Complete loss of CRADD expression during brain devel-
opment in Cradd/ mice resulted in megalencephaly
(Figure 4) and seizures without obvious changes in cortical
thickness or lamination (Figure S5). This is in distinct
contrast to the severe malformations of brain development
described above for caspase-3-, caspase-9-, and Apaf1-null
mice.
Previous work demonstrated that Casp2/ mice have
significantly reduced body weight and bone volume.57
We also observed reduced body weight in Cradd/
mice. Further study showed significantly decreased limb
size, indicating that the low weight correlated with small
body size (Table S2, Figure S6). The decreased body weight
and bone volume in Casp2/ and Cradd/ mice corre-
lates with our functional results, which demonstrate
loss of caspase-2 activation in the absence of active
CRADD. The head size of Casp2/ mice has not yet
been assessed.
CRADD activation of caspase-2 in neurons is required for
neurotrophic factor withdrawal-induced apoptosis and
for dendritic spine collapse and neuronal apoptosis in
response to amyloid-b aggregation,22,58 suggesting a role
for CRADD/caspase-2 signaling in synaptic plasticity and
cortical architecture during mammalian brain develop-
ment. The relative lack of a significant CNS phenotype in
early studies of Casp2/ mice and the mild megalence-
phaly described in this study for Cradd/mice, in contrast
to the lissencephaly variant and ID observed in CRADD-
TLIS-affected subjects, suggests that caspase-2 activity
may be less important in development of the mouse brain
than it is in the human brain.
Other Disorders Caused by Decreased Caspase-
Mediated Apoptosis
Caspase-dependent apoptosis is characterized by ordered
disruption of the cell without induction of inflamma-
tion.59 Caspase activation can be triggered by extracellular
signals (extrinsic pathway regulated by multiple death re-
ceptors) or intrinsic stress signals such as DNA damage
(intrinsic or mitochondrial pathway).60 Caspase-depen-
dent apoptosis is involved in several different human dis-
eases including neurodegenerative, cardiovascular, and
autoimmune disorders and cancer (reviewed by Favaloro
et al.59). Autoimmune lymphoproliferative syndrome is
a Mendelian disorder caused by impaired caspase-medi-
ated apoptosis (MIM: 601859, 603909, and 607271)61
associated with mutations in FAS,62 FASLG,63 CASP10,64
and CASP865 (MIM: 134637, 134638, 601762, and
601763, respectively). Individuals with this syndrome
develop chronic lymphoproliferation with lymphadenop-
athy, hepatosplenomegaly, autoimmunity, and increased
rates of malignancy61 but have normal development
and intellectual function.
Conclusions
Our data suggest that CRADD/caspase-2 signaling is
required for normal development of the human neocortex
and normal cognitive function and that decreased caspase-
2-mediated apoptosis during human development can
result in cortical malformation. Further investigation
is required to delineate the role of CRADD/caspase-2
signaling in homeostatic regulation of cortical devel-
opment. It is not clear whether the megalencephaly, un-
dulating pachygyria, increased cortical thickness, and
intellectual disability characteristic of CRADD-TLIS result
from reduced pruning of synaptic connections, decreased
programmed cell death of inappropriate neurons, or a
combination of the two.
Supplemental Data
Supplemental Data include seven figures and two tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2016.09.010.
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